Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 83.86

+1.3%

Dec 24 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (396)	9/25/2003 11:35:37 PM
From: Jibacoa	Read Replies (1) of 3722

INGN Has an important trading day coming tomorrow.<g> Today it was able to bounce back from its early intra-day L of 9.50 at 10.30AM and had good up-ticks in the early afternoon after its Investor Alert: "Introgen Therapeutics, Inc. has added a News Release to its Investor Relations web site. Title: Publication Shows Introgen's INGN 241 Drug Overcomes Common Cancer Toxicity Pathways Date: 9/25/2003 12:30:00 PM For a complete listing of our News Releases visit:" ir.ccbn.com A recent issue of the Journ. of Thor. and Cardiov. Surg. details the findings of a preclinical study in which therapy with INGN 241 causes lung cancer cells to undergo cell death through a unique mechanism of action. Dr. Stephen Swisher,the principal author of the publication said: "We have discovered that INGN 241 kills cancer cells in a novel and unique way. Our goal with this study was to find a way to circumvent certain processes in a tumor which make it resistant to treatment and we have shown that we can overcome that resistance cellularly to kill cancer cells effectively." In the study, they evaluated the molecular mechanisms underlying how INGN 241 kills lung cancer cells and their research showed that INGN 241 rapidly caused apoptosis, in tumor cells containing either normal or a mutated p53 gene. When compared to other vectors containing the bax or bak genes, INGN 241 had a significant advantage in that it did not kill normal cells. A number of commonly used chemotherapeutic drugs kill cells by activating mitochondrial proteins. This study shows that INGN 241 kills cancer cells independently of these mitochondrial drug-sensitive components, which could be an advantage in developing therapies to treat cancer patients whose tumors are resistant to chemotherapeutics. corporate-ir.net Although today's H was 3 cents higher than yesterday's (10.57 vs. 10.54 ), it is important that INGN, which has now closed its September 17 Up-gap, can overcome the resistance from the 10.54 to the September 17-September 22 and September 23 Hs at the 10.86 to 10.90 level.That is why IMHO it has an important trading day tomorrow.<g> siliconinvestor.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next